Jiann-Shiun Lai, PhD (賴建勳博士)

Senior Director, R&D Lab of OBI Pharma Inc.







Dr. Lai has over 20 years of R&D experiences in the development of biological drugs, especially the therapeutic monoclonal antibodies. Prior to joining OBI, he was the Advisor of Department of Industrial Technology, Ministry of Economic Affairs, sketching out the roadmap for antibody drug development and overseeing Technology Development Programs of organizations and biotech companies for MOEA.

During his stay in Development Center for Biotechnology, preceding his work at MOEA, he had successfully discovered, developed and licensed out two antibody drugs. Besides, he also established and supervised an antibody engineering team in DCB. Prior to this, Dr. Lai was a principle investigator in Academia Sinica more than nine years. During that period of time, his work focused on the understanding of the mechanism of VDJ recombination of immunoglobulin genes. Dr. Lai accomplished his postdoctoral training at MIT and received his Ph.D. degree from a joint program of SUNY Stony Brook and Cold Spring Harbor Laboratory.


About OBI Pharma, Inc. 台灣浩鼎

OBI Pharma, Inc., was founded in 2002. Its focus is on the “Unmet Medical Needs” in challenging diseases throughout the world, such as Cancer & Infectious Diseases. OBI strives to improve health and the quality of life through innovative and cost-effective therapeutics. OBI’s core competence is its R&D expertise in developing novel cancer and infectious disease therapies. The company has an exciting pipeline of products built on a ground-breaking carbohydrate synthesis discovery platform. OBI works in close collaboration with prestigious research institutes, including Academia Sinica of Taiwan and the Memorial Sloane-Kettering Cancer Center of the US.